Asis Shrestha, MD, FACP

Heme-onc Fellow @UAMShealth

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check @BloodCancerJnl #mmsm work led by @MansiShahMD : Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma

https://t.co/hh9hPn43Aq

➡️Baseline lymphocyte count is not predictive: 52% of patients had baseline lymphopenia, with similar ALC levels in responders (0.91 K/μL) vs non responders (0.92 K/μL), showing no association with survival outcomes
➡️Day 30 immune recovery strongly predicts survival: patients with poor day 30 immune scores had median PFS of 1 month and OS of 3 months, compared to not reached survival in those with good scores (p<0.001)

⭐️Early immune kinetics is a key prognostic indicator

@MeeraMohanMD @rajshekharucms @HadidiSamer @utswcancer @UAMSMyeloma @asis_shr @AnupTrix

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

How I Treat Plasma Cell Leukemia @ASH_hematology @utswcancer #mmsm

https://t.co/NgE8Qwy0Em

[Kostas Arnaoutakis @KArnaoutakis]

Five Stages of the Vail Workshop: A Fellow’s Perspective | ASCO Connection https://t.co/2PYKUE8pfX

Very proud of our fellow! @UAMS @uamshealth @uamscancer

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our recent work @UAMSMyeloma published @BloodAdvances :

Prognostic Impact of Focal Lesion Location and Persistence in Multiple Myeloma: Insights from Serial PET/DWI Imaging #mmsm

➡️https://t.co/DHuHGbopIl

n= 243 multiple myeloma patients followed 9.9 years with serial PET + DWI-MRI imaging:

✅81% had focal lesions (FL) at baseline
✅Imaging discordance: 74% detected by both modalities, 19% DWI-only, 7% PET-only - showing complementary value
✅61% had FL in long bones (humerus/femur) - these patients had 74% higher risk of progression (HR=1.74, p=0.0008)
🔄 Post-transplant: 33% had residual FL, but 82% were DWI-only positive vs 18% PET-positive, suggesting DWI more sensitive for residual disease detection
✅Patients with both MRD-negative + imaging-negative had best survival. BUT MRD-negative patients with persistent FL had outcomes as poor as double-positive patients (median PFS: 2.72 vs 2.1 years)
📍 At relapse: 84% of FL recurred at same/nearby original sites

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our recent work @BloodAdvances @UAMSMyeloma led by @asis_shr #mmsm

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

➡️n=16 sPCL, ORR: 31% (lower than typical MM ORR ~63%)
➡️Prior BCMA exposure = no response - all 4 patients with prior BCMA therapy failed to respond
➡️Responders had better outcomes but still limited - median PFS: 4.6 months, most progressed within 5 months, extremely short survival for non-responders: 18 days progression-free survival, ~1 month overall survival
➡️No grade 3-4 CRS observed

In general, better controlled disease results in better outcomes with the use of BCMA BsAbs

https://t.co/ScHvHQKPeH

[Jeff Sharman @jeff_sharman]

BTK inhibitors have transformed the lives of many patients with Chronic Lymphocytic Leukemia and other lymphomas. These drugs "exploded" onto the scene in 2013-2014 and have fundamentally changed the way we treat the disease. What many people don't know is how it all happened..

[Asis Shrestha, MD, FACP @asis_shr]

We present two cases of COVID-19 induced ITP in Multiple myeloma patients, both of whom were successfully treated for ITP and relapsed multiple myeloma with teclistamab. @AnupTrix @UAMSMyeloma #ITP #Myeloma #Teclistamab

https://t.co/5zg3UTp9YT

[UAMS Myeloma Center @UAMSMyeloma]

Story in the Winter 2024/2025 Myeloma Magazine on hospitalists at @uamscancer and their role in treating #MultipleMyeloma patients, including @AnupTrix, @asis_shr and @MujtabaNaqvi20. https://t.co/lAydKGcSq5 #uamsmyeloma #uamscancer #WPRCI #uamshealth #mmsm

[Asis Shrestha, MD, FACP @asis_shr]

It was truly inspiring to connect with Dr. Dhakal @bhemato and Dr Devendra KC at #ASH24

[Asis Shrestha, MD, FACP @asis_shr]

It was a pleasure meeting with Dr. Shah, @binayshah at #ASH24.

[Asis Shrestha, MD, FACP @asis_shr]

UAMS team gathering at poster 3789 #ASH24 presented by @Dr_Bhavesh_M

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

@HadidiSamer @AnupTrix @sruthivellankiT

[Asis Shrestha, MD, FACP @asis_shr]

Taking a break amidst the conference… recharging for next sessions!!! with Dr. Schinke and Dr. Thanendrarajan #ash24

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm @ASH_hematology

Oral Myeloma:Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Prior Transplant in retrospective analysis is associated with lower PFS when receiving BCMA CAR-T compared to no prior transplant though no OS difference

Be careful with interpretation- one notable difference is time from diagnosis to either transplant vs. CAR-T indicating those patients population are different

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm @ASH_hematology

Myeloma orals: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

This is the 2nd presentation indicating that our current response assessment need modification which is apparently happening and that includes the need for repeat confirmatory test to identify progressions

[Asis Shrestha, MD, FACP @asis_shr]

Excited to share that I’ve matched into Hematology-Oncology Fellowship at the University of Arkansas for Medical Sciences. Thrilled to begin this incredible journey of learning, research, and patient care. Thank you to everyone who has supported me along the way. Here’s to the future! #FellowshipMatch2024

[Muzaffar Qazilbash @Transplant_Doc]

#ASH24 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702. *Omitting 24HRU assessments from IMWG criteria changed <1% of responses and had no impact on PFS prediction at any response depth #mmsm #bmtsm @R@RahulBanerjeeMD https://t.co/BSlqBXLRc3